Alpha Cognition Inc
XTSX:ACOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alpha Cognition Inc
XTSX:ACOG
|
CA |
|
Ideanomics Inc
OTC:IDEX
|
US |
|
F
|
FendX Technologies Inc
CNSX:FNDX
|
CA |
|
Ranger Energy Services Inc
NYSE:RNGR
|
US |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SZSE:300619
|
CN |
|
P
|
PKU HealthCare Corp Ltd
SZSE:000788
|
CN |
|
R
|
Roxas Holdings Inc
XPHS:ROX
|
PH |
|
GEPIC Energy Development Co Ltd
SZSE:000791
|
CN |
|
Osisko Development Corp
XTSX:ODV
|
CA |
|
V
|
Vocera Communications Inc
F:V00
|
US |
|
C
|
Circa Group AS
OSE:CIRCA
|
NO |
Alpha Cognition Inc
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.
